Nektar Therapeutics Accounts Payable
Nektar Therapeutics (NKTR) had Accounts Payable of $24.89 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-14
- 2026-06-30: Accounts Payable, Current $24.89M.
- 2026-03-31: Accounts Payable, Current $10.03M.
- 2025-12-31: Accounts Payable, Current $10.77M.
- 2025-09-30: Accounts Payable, Current $15.56M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $24.89M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $10.03M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $10.77M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $15.56M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $14.28M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $17.83M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $11.56M 10-K · filed 2026-03-13 |
| 2024-09-30 | $8.58M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $6.47M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $8.76M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $9.85M 10-K · filed 2025-03-14 |
| 2023-09-30 | $3.29M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $2.62M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $3.70M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $12.98M 10-K · filed 2024-03-05 |
| 2022-09-30 | $5.33M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $12.35M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $12.62M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $9.75M 10-K · filed 2023-02-28 |
| 2021-09-30 | $23.66M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $19.70M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $22.43M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $22.14M 10-K · filed 2022-03-01 |
| 2020-09-30 | $15.48M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $19.25M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $21.79M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $19.23M 10-K · filed 2021-02-26 |
| 2019-09-30 | $21.96M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $9.35M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $11.01M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $5.85M 10-K · filed 2020-02-28 |
| 2018-09-30 | $7.49M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $10.67M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $11.38M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $4.78M 10-K · filed 2019-03-01 |
| 2017-09-30 | $8.56M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $6.24M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $6.95M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $2.82M 10-K · filed 2018-03-01 |
| 2016-09-30 | $7.12M 10-Q · filed 2016-11-04 |
| 2016-06-30 | $2.33M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $2.35M 10-Q · filed 2016-05-04 |
| 2015-12-31 | $2.36M 10-K · filed 2017-03-01 |
| 2015-09-30 | $2.28M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $2.83M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $5.02M 10-Q · filed 2015-05-01 |
| 2014-12-31 | $2.70M 10-K · filed 2016-02-29 |
| 2014-09-30 | $5.43M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $7.44M 10-Q · filed 2014-08-01 |
| 2014-03-31 | $3.06M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $9.12M 10-K · filed 2015-02-26 |
| 2013-09-30 | $3.72M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $5.57M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $4.22M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $2.86M 10-K · filed 2014-02-27 |
| 2012-09-30 | $2.62M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $3.12M 10-Q · filed 2012-08-09 |
| 2012-03-31 | $1.76M 10-Q · filed 2012-05-04 |
| 2011-12-31 | $3.02M 10-K · filed 2013-03-01 |
| 2011-09-30 | $2.17M 10-Q · filed 2011-11-04 |
| 2011-06-30 | $3.24M 10-Q · filed 2011-08-05 |
| 2011-03-31 | $3.48M 10-Q · filed 2011-04-29 |
| 2010-12-31 | $7.19M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |